Kai Tak, K3CIK 17825394 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
27 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Evommune Inc | 1.44M | $24.67M | 22.1% | +1.44M | New |
| 2 | Maplight Therapeutics Inc | 971.3K | $17.06M | 15.3% | +971.3K | New |
| 3 | Oculis Holding AG | 514.7K | $10.28M | 9.2% | 0 | Held |
| 4 | Madrigal Pharmaceuticals Inc |
| 11.9K |
| $6.91M |
| 6.2% |
| 0 |
| Held |
| 5 | Lb Pharmaceuticals Inc | 300.0K | $6.68M | 6.0% | 0 | Held |
| 6 | Incyte Corp | 59.0K | $5.83M | 5.2% | 0 | Held |
| 7 | Rhythm Pharmaceuticals Inc | 49.1K | $5.26M | 4.7% | 0 | Held |
| 8 | Beone Medicines Ltd | 15.7K | $4.78M | 4.3% | 0 | Held |
| 9 | Procore Technologies Inc | 53.3K | $3.88M | 3.5% | +53.3K | New |
| 10 | Cybin Inc | 460.0K | $3.76M | 3.4% | +460.0K | New |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio